Download PDF
Synthesis 2021; 53(22): 4231-4238
DOI: 10.1055/s-0040-1706046
special topic
Special Issue dedicated to Prof. Sarah Reisman, recipient of the 2019 Dr. Margaret Faul Women in Chemistry Award

Synthesis of Borylated Hydrazino Acid Derivatives

Chieh-Hung Tien
,
Alina Trofimova
,
Wenjie Shao
,
Andrei K. Yudin∗
The Natural Sciences and Engineering Research Council of Canada is gratefully acknowledged for their financial support. C.-H. T. would like to thank the Connaught Fund (University of Toronto).
› Further Information
   Permissions and Reprints All articles of this category


Abstract

α-Boryl-α-hydrazinoacetic acid is a highly functionalized boron-containing building block that can be easily accessed from readily available α-borylacetaldehyde. The hydrazine motif can be converted into a variety of α-borylated azoles and diazines in a straightforward protocol. Furthermore, the carboxy group can be derivatized to afford novel organoboron compounds that should find applications in various cross-coupling transformations.

Key words

hydrazinoboronates - aminoboronic acids - organoboron - borylated heterocycles - BMIDA

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0040-1706046.
  • Supporting Information


Publication History

Received: 04 April 2021

Accepted after revision: 07 May 2021

Article published online:
31 May 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

    • 1a Wu X, Chen X.-X, Fossey JS, James TD, Jiang Y.-B. Chem. Soc. Rev. 2013; 42: 8032
      CrossrefPubMed
    • 1b Dimitrijević E, Taylor MS. ACS Catal. 2013; 3: 945
      CrossrefPubMed
    • 1c Li J, Ballmer SG, Gillis EP, Fujii S, Schmidt MJ, Palazzolo AM. E, Lehmann JW, Morehouse GF, Burke MD. Science 2015; 347: 1221
      CrossrefPubMed
    • 1d Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Chem. Rev. 2012; 112: 4156
      CrossrefPubMed
  • 2 Diaz DB, Yudin AK. Nat. Chem. 2017; 9: 731
    CrossrefPubMed
    • 3a Chen D, Frezza M, Schmitt S, Kanwar J, Dou D.-P. Curr. Cancer Drug Targets 2011; 11: 239
      CrossrefPubMed
    • 3b Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. Cancer Res. 2004; 64: 5471
      CrossrefPubMed
    • 3c Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Int. Immunopharmacol. 2012; 12: 257
      CrossrefPubMed
    • 3d Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PR. S, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP. III, Karlowsky JA. Drugs 2018; 78: 65
      CrossrefPubMed
    • 3e Milo LJ. Jr, Lai JH, Wu W, Liu Y, Maw H, Li Y, Jin Z, Shu Y, Poplawski SE, Wu D, Sanford DG, Sudmeier JL, Bachovchin WW. J. Med. Chem. 2011; 54: 4365
      CrossrefPubMed
    • 4a Andrés P, Ballano G, Calaza I, Cativiela C. Chem. Soc. Rev. 2016; 45: 2291
      CrossrefPubMed
    • 4b Beenen MA, An C, Ellman JA. J. Am. Chem. Soc. 2008; 130: 6910
      CrossrefPubMed
    • 4c Zajdlik A, Wang Z, Hickey JL, Aman A, Schimmer AD, Yudin AK. Angew. Chem. Int. Ed. 2013; 52: 8411
      CrossrefPubMed
    • 4d Diaz DB, Scully CC. G, Liew SK, Adachi S, Trinchera P, St Denis JD, Yudin AK. Angew. Chem. Int. Ed. 2016; 55: 12659
      CrossrefPubMed
    • 4e Shiro T, Schuhmacher A, Jackl MK, Bode JW. Chem. Sci. 2018; 9: 5191
      CrossrefPubMed
    • 4f Reyes RL, Sato M, Iwai T, Sawamura M. J. Am. Chem. Soc. 2020; 142: 589
      CrossrefPubMed
  • 5 Fustero S, Sánchez-Roselló M, Barrio P, Simón-Fuentes A. Chem. Rev. 2011; 111: 6984
    CrossrefPubMed
    • 6a Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. Molecules 2020; 25: 1909
      CrossrefPubMed
    • 6b Lamberth C. Heterocycles 2007; 71: 1467
      Crossref
    • 6c Da Costa L, Scheers E, Coluccia A, Casulli A, Roche M, Di Giorgio C, Neyts J, Terme T, Cirilli R, La Regina G, Silvestri R, Mirabelli C, Vanelle P. J. Med. Chem. 2018; 61: 8402
      CrossrefPubMed
    • 7a Salaün A, Potel M, Roisnel T, Gall P, Le Grel P. J. Org. Chem. 2005; 70: 6499
      CrossrefPubMed
    • 7b Acherar S, Salaün A, Le Grel P, Le Grel B, Jamart-Grégnoire B. Eur. J. Org. Chem. 2013; 2013: 5603
    • 7c Avan I, Hall CD, Katritzky AR. Chem. Soc. Rev. 2014; 43: 3575
      CrossrefPubMed
    • 7d Suć J, Tumir L.-M, Glavaš-Obrovac L, Jukic M, Piantanida I, Jerić I. Org. Biomol. Chem. 2016; 14: 4865
      CrossrefPubMed
    • 8a He Z, Yudin AK. J. Am. Chem. Soc. 2011; 133: 13770
      CrossrefPubMed
    • 8b He Z, Trinchera P, Adachi S, St Denis JD, Yudin AK. Angew. Chem. Int. Ed. 2012; 51: 11092
      CrossrefPubMed
    • 8c St Denis JD, Zajdlik A, Tan J, Trinchera P, Lee CF, He Z, Adachi S, Yudin AK. J. Am. Chem. Soc. 2014; 136: 17669
      CrossrefPubMed
    • 8d Kaldas SJ, O’Keefe KT, Mendoza-Sanchez R, Yudin AK. Chem. Eur. J. 2017; 23: 9711
      CrossrefPubMed
    • 8e Holownia A, Tien C.-H, Diaz DB, Larson RT, Yudin AK. Angew. Chem. Int. Ed. 2019; 58: 15148
      CrossrefPubMed
    • 9a List B. J. Am. Chem. Soc. 2002; 124: 5656
      CrossrefPubMed
    • 9b Bøgevig A, Kumaragurubaran N, Juhl K, Zhuang W, Jørgensen KA. Angew. Chem. Int. Ed. 2002; 41: 1790
      CrossrefPubMed
  • 10 Based on separation by HPLC on a chiral stationary phase column (see Supporting Information), the e.r. of 6d, and thus 1 by correlation, was determined to be 60:40. Due to the almost racemic nature of 1, e.r. determination of derivatives 5 and 6 were not measured.
  • 11 Ivon YM, Mazurenko IV, Kuchkovska YO, Voitenko ZV, Grygorenko OO. Angew. Chem. Int. Ed. 2020; 59: 18016
    CrossrefPubMed
  • 12 Bindal S, Kumar D, Kommi DN, Bhatiya S, Chakraborti AK. Synthesis 2011; 1930
  • 13 Hou T.-C, Wu Y.-Y, Chiang P.-Y, Tan K.-T. Chem. Sci. 2015; 6: 4643
    CrossrefPubMed